Treatment of a coronary condition by delivery of therapeutics to the pericardial space
First Claim
Patent Images
1. A method of treatment or prevention of a coronary condition comprising:
- (a) providing a first pharmaceutical composition comprising a therapeutically effective amount of a first therapeutic agent, and (b) administering the first pharmaceutical composition to the pericardial space of a patient.
0 Assignments
0 Petitions
Accused Products
Abstract
The invention is a treatment for coronary conditions by delivering a therapeutic agent to the pericardial space. The therapeutic agent can be delivered by internal entry through the atrium or venticle, or by external entry through the chest cavity. The therapeutic agent can be a polypeptide, polynucleotide or other drug.
58 Citations
100 Claims
-
1. A method of treatment or prevention of a coronary condition comprising:
-
(a) providing a first pharmaceutical composition comprising a therapeutically effective amount of a first therapeutic agent, and (b) administering the first pharmaceutical composition to the pericardial space of a patient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 60, 62, 63, 64, 65, 66, 68, 69, 70, 71, 98, 99, 100)
-
-
72. A method of treating cardiac muscle tissue comprising:
-
(a) identifying an infarct or ischemic zone, (b) accessing a pericardial space in the region of the infarct or ischemic zone, and (c) delivering a pharmaceutical composition comprising a therapeutic agent to the region of the infarct or ischemic zone. - View Dependent Claims (73, 74, 75, 76, 77, 78, 79)
-
-
80. A method of accessing the pericardial space for administration of a therapeutic agent to the pericardial space comprising:
-
(a) providing an agent capable of lysing a pericardial/epicardial adhesion, (b) administering the agent to the pericardial space. - View Dependent Claims (81, 82, 83, 84, 85)
-
-
86. Use of a therapeutic agent administered intrapericardially to treat a coronary condition wherein the therapeutic agent is selected from the group consisting of an anti-apoptotic agent, a thrombolytic agent, a pro-angiogenic agent, an anti-arrythmic agent, a contractility improving agent, a complement blocker, an inhibitor of reperfusion injury, a calcium channel blocker, a beta-blocker, an afterload reducer, a preload reducer, a vasoactive agent, an anti-thrombotic agent, an anti-platelet agent, anti-proliferative agent, an anti-inflammatory agent, an immunomodulating agent, an immunosuppressive agent, an inhibitor of reactive oxygen metabolites, an anti-angiogenic agent, a myocyte growth factor, a vasoactive agent, a cardioprotective agent, an iron-chelating agent, an anti-hypertensive agent, an anti-integrin agent, a pro-apoptotic agent, an anti-viral agent, an anti-parasitic agent, a free radical scavenger, a protein that may be deficient or downregulated during development of cardiomyopathy, and biologically active derivatives thereof.
-
87. Use of a therapeutic agent administered intrapericardially to treat a coronary condition wherein the therapeutic agent is selected from the group consisting of tissue plasminogen activator (tPA), an inhibitor of interleukin 1β
- converting enzyme, urokinase plasminogen activator (uPA), urokinase, streptokinase, an inhibitor of α
2 plasmin inhibitor, an inhibitor of plasminogen activator inhibitor-1 (PAI-1), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), vascular endothelial cell growth factor (VEGF), angiogenin, transforming growth factor α
(TGF-α
), transforming growth factor β
(TGF-β
), tumor necrosis factor-α
(TNF-α
), platelet derived growth factor (PDGF), placental growth factor (PGF), hepatocyte growth factor, proliferin, decay accelerating factor, CAB-2, tissue factor pathway inhibitor (TFPI), heparin, hirudin, protein C, protein S, anti-thrombin III, tick anti-coagulant peptide (TAP), anti-stasin, glycoprotein IIb/IIa antagonist, antibodies, Herpes thymidine kinase, fas, faf, platelet factor 4, thrombospondin, a tissue inhibitor of a metalloproteinase, prolactin, bFGF soluble receptor, a proliferin-related protein, myocyte growth factor, superoxide dismutase (SOD), troponin C, beta-adrenergic receptor, insulin-like growth factor I (IGF-I), nematode anti-coagulant protein (NAP), biologically active fragments thereof, and chimeras thereof, to treat a coronary condition.
- converting enzyme, urokinase plasminogen activator (uPA), urokinase, streptokinase, an inhibitor of α
-
88. Use of intrapericardially delivered troponic C to treat cardiomyopathy.
-
89. Use of an intrapericardially delivered anti-tumor agent selected from the group consisting of a chemotherapeutic agent, a radiation sensitizer, and a radioactive implant to treat heart cancer.
-
90. Use of an intrapericardially delivered inhibitor selected from the group consisting of an inhibitor of lipid or cholesterol synthesis or deposition, an inhibitor of macrophage or inflammatory cell recruitment or activation, a microtubule inhibitor, an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, and an inhibitor of neointimal proliferation to treat a cardiovascular indication.
-
91. Use of an intrapericardially delivered anti-proliferative agent to treat a coronary condition characterized by cell-proliferation selected from the group consisting of a ribozyme, an antisense oligonucleotide, an antibody, an inhibitor against c-myb, ras, raf, PI3 kinase, or cyclin, a suicide protein, a suicide gene, a proapoptotic protein, and a proapoptotic gene.
-
92. Use of an intrapericardially delivered anti-angiogenic agent to treat a coronary condition selected from the group consisting of platelet factor 4, thrombospondin, a tissue inhibitor of a metaloproteinase, angiostatin, TFG-β
- , interferon-α
, a proliferin-related protein, biologically active fragments thereof, and chimeras thereof.
- , interferon-α
-
93. Use of an intrapericardially delivered antibiotic selected from the group consisting of an anti-viral agent, anti-trypanosomal agent, anti-bacterial agent, and an anti-fungal agent to treat a coronary infection.
-
94. Use of an intrapericardially delivered immunomodulating agent selected from the group consisting of a cytotoxic agent, a steroid, cyclosporin, and a complement inhibitor to treat a coronary condition.
-
95. Use of an intrapericardially delivered antiinflammatory agent selected from the group consisting of a steroid, a non-steroidal antiinflammatory agent, cyclosporin, a chemotherapeutic agent, and a complement inhibitor to treat a coronary condition characterized by inflammation.
-
96. Use of an intrapericardially delivered anti-arrhythmic agent selected from the group consisting of adenosine, quinidine, propranolol, digoxin, lidocaine, bretylium, amiodarone, and verapamil to treat a coronary condition.
-
97. Use of an intrapericardially delivered anti-hypertensive agent selected from the group consisting of hydralazine, propranolol, atrial naturetic peptide, and an endothelin antagonist to treat a coronary condition.
Specification